Shionogi stock
4507.TJPXShionogi & Co., Ltd., HealthcareISIN JP3347200002
81Score 81 out of 100, Strong
Price and trend
68 / 100
Price history
+17% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 3.7% above it.
Since July 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 60).
The price is 13% below its 52-week high. Largest decline in 20 years: 65% (August 2008 to November 2011).
Chart figures for advanced users
- SMA 50$18.37
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$19.23
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)60
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$15.55
- The lowest closing price of the last twelve months.
- Resistance$22.94
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Shionogi & Co., Ltd. belongs to the Drug Manufacturers (Specialty & Generic) industry (Japan) and, with a market value of $16.97B, is number 16 of 77 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.13B (up 14% year on year) and earnings of $1.28B (up 20.4%).
- For fiscal 2026, analysts expect on average revenue of $4.51B (up 44%) and adjusted earnings per share of $1.71 (up 11.5%).
Show more
- MEQIRI Score 81 out of 100 (Strong): rank 14 of 702 in Healthcare, median 53.
- The P/E is 11.3 (Drug Manufacturers (Specialty & Generic) median 32.5, own median of recent years 15.2).
- Our model puts fair value at $33.02, with the price 40% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Modestly valuedP/E 11.3, Drug Manufacturers (Specialty & Generic) median 32.5, own median 15.2.Valuation 90
- High marginNet margin 37.9% over the last 12 months, Drug Manufacturers (Specialty & Generic) median 15.5%.Profitability 82
- Below fair valuePrice 40% below the fair value of $33.02.Valuation 90
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are valuation and growth.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Significantly undervaluedClosing price of 12 Nov 2026, used by the daily score.
In our model the price counts as cheap below $23.59 and expensive above $55.03 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $8.35 (cash-flow model) and $57.69 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 6.1%. At 7.1% the fair value would be $32.32, at 5.1% it would be $34.06.
Valuation metrics
Half from the dividend model, half from earnings times the industry P/E (32.5).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 45.7% on the twelve months before. Revenue has grown solidly since 2006, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 82%, operating 32%, net 41%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 5 Feb 2027in 84 days
- Last reported
- 29 Oct 2026EPS reported $0.16 (expected $0.27)below expectations
Analyst estimates
Earnings estimates have barely changed since 22 Oct 2026.
- Earnings per share
- $1.71−0.4%
- Revenue
- $4.51B+0.6%
- Earnings per share
- $1.71−1.5%
- Revenue
- $4.79B+1.1%
MEQIRI has stored the estimates since 22 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Shionogi
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 81
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Hansoh Pharmaceutical Group3692.HK $26.89B79
- ViatrisVTRS $23.7B55
- Torrent PharmaceuticalsTORNTPHARM.NS $19.11B63
- PharmaEssentia6446.TW $17.18B71
- IpsenIPN.PA $15.31B75
- Yunnan Baiyao Group000538.SZ $14.63B67
- Laurus LabsLAURUSLABS.NS $13.78B70
- Elanco Animal HealthELAN $13.25B48
ETFs that hold Shionogi
Held by 100 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| UBS MSCI Japan Climate Paris Aligned UCITS ETF ir-hEUR accAW1Q | 2.95% | 0.15% | €194.25M |
| iShares MSCI Japan CTB Enhanced ESG UCITS ETF EUR Hedged AccCEB3 | 1.51% | 0.18% | €115.68M |
| iShares Healthcare Innovation UCITS ETF2B78 | 1.37% | 0.40% | €1.5B |
Show 5 more
| Amundi MSCI Japan ESG Broad Transition UCITS ETF EUR AccJ1GR | 1.14% | 0.15% | €1.36B |
| iShares MSCI Japan SRI UCITS ETFSXR6 | 1.02% | 0.20% | €435.69M |
| Xtrackers MSCI Japan ESG UCITS ETF 1CXZMJ | 0.61% | 0.20% | €2.71B |
| Amundi MSCI Pacific ESG Broad Transition UCITS ETF DistX014 | 0.60% | 0.45% | €179.33M |
| Xtrackers Nikkei 225 UCITS ETF 2D EUR HedgedXDJE | 0.53% | 0.19% | €2.61B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 13 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ¥159.70)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 6 Dec 2024)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.